We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why It is Worth Investing in Nordson Stock Right Now
Read MoreHide Full Article
Key Takeaways
NDSN is seeing recovery in Medical and Fluid Solutions, with organic sales in the unit up 7.4%.
Acquisitions like Atrion lifted NDSN's fiscal 2025 revenues, expanding its medical portfolio.
Nordson boosted shareholder returns via higher dividends, aggressive buybacks and rising earnings estimates.
Nordson Corporation (NDSN - Free Report) stands to benefit from strength across its businesses, focus on operational excellence and acquired assets. The company remains focused on investing in growth opportunities and strengthening its long-term market position.
NDSN, which has a market capitalization of $13.4 billion, currently carries a Zacks Rank #2 (Buy). Let’s delve into the factors that have been aiding the firm for a while now.
End-Market Strength: Nordson is poised to gain from its diversified business structure, which helps mitigate the adverse impact of weakness in one end market with strength across the others. The company is witnessing a strong recovery in the Medical and Fluid Solutions segment, organic sales from which increased 7.4% year over year in the fourth quarter of fiscal 2025 (ended October 2025).
Strength across the medical interventional product lines, owing to growing demand and a healthy pipeline of customer projects, is boosting the segment’s performance. Increased demand for medical fluid components and fluid solutions product lines is aiding the segment. Healthy demand for electronic processing and optical sensors, and electronics dispensing product lines within the semiconductor and electronics end markets holds positive for the Advanced Technology Solutions segment.
Acquisition Benefits: The company intends to strengthen and expand its businesses through acquisitions. In August 2024, Nordson completed the acquisition of Atrion Corp. The inclusion of Atrion’s three major businesses — Halkey Roberts, Atrion Medical and Quest Medical — enabled the company to expand its medical offerings in the infusion and cardiovascular therapies market. The buyout was combined with Nordson's medical business. In fiscal 2025, acquired assets boosted the company’s total revenues by 6%.
Price Performance of NDSN Stock
Image Source: Zacks Investment Research
In the past year, the company’s shares have gained 14.8% compared with the industry’s 7.3% growth.
Shareholder-Friendly Policies: Nordson remains committed to increasing shareholders’ value through dividend payments and share repurchases. In fiscal 2025, Nordson paid out dividends of $179.1 million, up 11% year over year. In the same period, it bought back treasury shares worth $306.4 million compared with $33.3 million in the year-ago period. In August 2025, the company hiked its dividend by 5% to 82 cents per share.
Upward Estimate Revisions: In the past 30 days, the Zacks Consensus Estimate for Nordson’s fiscal 2026 (ending October 2026) earnings has trended up from $10.94 per share to $11.19 on four upward estimate revisions against none downward. The consensus estimate for fiscal 2027 (ending October 2027) earnings increased from $12.00 per share to $12.11 on one upward estimate revision against none downward.
Other Key Picks
Some other top-ranked companies from the same space are discussed below.
HLIO delivered a trailing four-quarter average earnings surprise of 16.8%. In the past 60 days, the consensus estimate for Helios’ 2025 earnings has increased 1.7%.
Parker-Hannifin Corporation (PH - Free Report) presently carries a Zacks Rank of 2. PH delivered a trailing four-quarter average earnings surprise of 6.2%.
In the past 60 days, the consensus estimate for Parker-Hannifin’s fiscal 2026 earnings has increased 3.8%.
Trimble Inc. (TRMB - Free Report) currently carries a Zacks Rank of 2. TRMB delivered a trailing four-quarter average earnings surprise of 7.4%. In the past 60 days, the Zacks Consensus Estimate for Trimble’s 2025 earnings has increased 3.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why It is Worth Investing in Nordson Stock Right Now
Key Takeaways
Nordson Corporation (NDSN - Free Report) stands to benefit from strength across its businesses, focus on operational excellence and acquired assets. The company remains focused on investing in growth opportunities and strengthening its long-term market position.
NDSN, which has a market capitalization of $13.4 billion, currently carries a Zacks Rank #2 (Buy). Let’s delve into the factors that have been aiding the firm for a while now.
End-Market Strength: Nordson is poised to gain from its diversified business structure, which helps mitigate the adverse impact of weakness in one end market with strength across the others. The company is witnessing a strong recovery in the Medical and Fluid Solutions segment, organic sales from which increased 7.4% year over year in the fourth quarter of fiscal 2025 (ended October 2025).
Strength across the medical interventional product lines, owing to growing demand and a healthy pipeline of customer projects, is boosting the segment’s performance. Increased demand for medical fluid components and fluid solutions product lines is aiding the segment. Healthy demand for electronic processing and optical sensors, and electronics dispensing product lines within the semiconductor and electronics end markets holds positive for the Advanced Technology Solutions segment.
Acquisition Benefits: The company intends to strengthen and expand its businesses through acquisitions. In August 2024, Nordson completed the acquisition of Atrion Corp. The inclusion of Atrion’s three major businesses — Halkey Roberts, Atrion Medical and Quest Medical — enabled the company to expand its medical offerings in the infusion and cardiovascular therapies market. The buyout was combined with Nordson's medical business. In fiscal 2025, acquired assets boosted the company’s total revenues by 6%.
Price Performance of NDSN Stock
Image Source: Zacks Investment Research
In the past year, the company’s shares have gained 14.8% compared with the industry’s 7.3% growth.
Shareholder-Friendly Policies: Nordson remains committed to increasing shareholders’ value through dividend payments and share repurchases. In fiscal 2025, Nordson paid out dividends of $179.1 million, up 11% year over year. In the same period, it bought back treasury shares worth $306.4 million compared with $33.3 million in the year-ago period. In August 2025, the company hiked its dividend by 5% to 82 cents per share.
Upward Estimate Revisions: In the past 30 days, the Zacks Consensus Estimate for Nordson’s fiscal 2026 (ending October 2026) earnings has trended up from $10.94 per share to $11.19 on four upward estimate revisions against none downward. The consensus estimate for fiscal 2027 (ending October 2027) earnings increased from $12.00 per share to $12.11 on one upward estimate revision against none downward.
Other Key Picks
Some other top-ranked companies from the same space are discussed below.
Helios Technologies, Inc. (HLIO - Free Report) presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
HLIO delivered a trailing four-quarter average earnings surprise of 16.8%. In the past 60 days, the consensus estimate for Helios’ 2025 earnings has increased 1.7%.
Parker-Hannifin Corporation (PH - Free Report) presently carries a Zacks Rank of 2. PH delivered a trailing four-quarter average earnings surprise of 6.2%.
In the past 60 days, the consensus estimate for Parker-Hannifin’s fiscal 2026 earnings has increased 3.8%.
Trimble Inc. (TRMB - Free Report) currently carries a Zacks Rank of 2. TRMB delivered a trailing four-quarter average earnings surprise of 7.4%. In the past 60 days, the Zacks Consensus Estimate for Trimble’s 2025 earnings has increased 3.3%.